Podcasts about Clinical research

Meet Tess Zigo, CFP, CPA olsenna.com Olsen Facebook Olsen Instagram Olsen Linkedin Olsen Youtube https://www.oneplacecapital.com/ Follow @dental_digest_podcast Instagram Follow @dr.melissa_seibert on Instagram Connect with Melissa on Linkedin Dr. Peter Milgrom is Professor of Oral Health Sciences and Pediatric Dentistry in the School of Dentistry and adjunct Professor of Health Services in the School of Public Health at the University of Washington. He directs the Northwest Center to Reduce Oral Health Disparities. He holds academic appointments at Case Western University, University of Rochester, and University of California, San Francisco. He maintains a dental practice limited to the care of fearful patients and served as Director of the UW Dental Fears Research Clinic. Dr. Milgrom's work includes research on xylitol, the effectiveness of fluoride varnish and iodine in preschoolers, clinical efficacy and safety of diammine silver fluoride, motivational strategies to increase perinatal and well child dental visits in rural communities, and studies of cognitive interventions in pediatric and adult dental fear. The NIH, Maternal and Child Health Bureau, HRSA, and the Robert Wood Johnson Foundation support his work. Dr. Milgrom is author of 5 books and over 300 scientific articles. His latest book, Treating Fearful Dental Patients, was published in 2009.   Dr. Milgrom was Distinguished Dental Behavioral Scientist of the International Association for Dental Research for 1999. In 1999, and again in 2000, his work was recognized by the Giddon Award for research in the behavioral sciences in Dentistry. He received the Barrows Milk Award from IADR in 2000, recognizing his work for public health including the development of the Access to Baby and Child Dentistry (ABCD) program in Washington State. In 2003, Dr. Milgrom received a Special Commendation Award from the National Legal Aid and Defenders Association and the University of Washington Medical Center Martin Luther King, Jr. Community Service Award. In 2010, he received the Aubrey Sheiham Research Award for his work on xylitol. He serves on scientific review committees for the NIDCR, NIMHHD, NINDS, Center for Scientific Review at NIH and as a consultant to the FDA. In 2005, Dr. Milgrom was appointed the SAAD Visiting Professor of Pain and Anxiety Control at the King's College Dental Institute, University of London, UK for a six-year term. In 2008 he was awarded the degree of Doctor Honoris Causa from the University of Bergen, Norway in recognition of his work in social and behavioral dentistry. In 2012, he received the University of California, San Francisco Dental Alumni Gold Medal for his contributions to Dentistry. In 2012 he was also awarded the Norton Ross Award for Excellence in Clinical Research by the American Dental Association. In 2013, he was appointed to the Council of Scientific Affairs of the American Dental Association. In 2014, he received the Irwin M. Mandel Distinguished Mentor Award from the IADR. In 2015, he served as HMDP Expert in Dental Public Health for the Singapore Ministry of Health. Dr. Milgrom received his DDS from the University of California, San Francisco in 1972 and had a previous position at the National Academy of Sciences, Engineering, and Medicine. In the last few years, Dr. Milgrom has spoken to dental associations in Argentina, Colombia, Peru, Philippines, and USA and at major universities in USA and abroad.

JAMA Editor-in-Chief Kirsten Bibbins-Domingo, MD, PhD, joins to discuss how JAMA and the JAMA Network are moving faster and adapting to the rapid changes in medical research after the pandemic. American Medical Association CXO Todd Unger hosts.

OIS Podcast host Carey Powers caught up with four ophthalmology execs and one principal investigator to talk about some of the most exciting developments in retina R&D.Her guests include:Houman David Hemmati, MD, PhD, Cofounder and Chief Medical Officer of Optigo Biotherapeutics   Michael Tsipursky, MD, CEO and Cofounder of Revive BiotechMichael Singer, MD, Clinical Professor of Ophthalmology at University of Texas Health Science Center, Director of Clinical Research at Medical Center Ophthalmology Associates, and Principal Investigator for Unity Biotechnology's BEHOLD trialSamarendra Mohanty, PhD, President and Cofounder; and Sulagna Bhattacharya, CEO and Cofounder of Nanoscope TherapeuticsOptigo is developing binders intended to extend the duration of top-performing intravitreal drugs without compromising efficacy. The company has already had promising results in clinical trials with aflibercept. What's next?Revive Biotech focuses on central retinal artery occlusion. Its products work by injecting oxygen-loaded nanobubbles into the eye intravitreally. Preclinical studies have advanced through proof of concept. Nanobubbles?Dr. Singer is a principal investigator in Unity Biotechnology's clinical trial for UBX-1325, a therapeutic in development to treat diabetic macular edema and wet AMD. If approved, the product could work as an adjunct to anti-VEGF therapies.Nanoscope Therapeutics is developing gene therapies that focus on ambient light-sensitive molecules to treat inherited and acquired retinal diseases. Its lead product, MCO-010, is moving through Phase II trials. Why ambient light?Tune in to hear today's experts discuss:How Optigo plans to extend the duration of afliberceptThe impact of extending duration activity on patients, physicians, and payersWhat Optigo plans to accomplish over the next 12 monthsWhat's behind Revive Biotech's proprietary technology and what makes it unique.The milestones it has completed so far with relation to clinical trials, intellectual property, and fundingThe new class of therapeutics being developed by Unity BiotechnologyThe data released so far on the UBX-1325 BEHOLD trialIf approved, the impact of UBX-1325—an agent that may potentially extend the life of anti-VEGF therapies—on clinical practiceThe potential impact of Nanoscope Therapeutics's MCO-010 on patient communitiesThe feedback reported from clinical trial participantsThe critical milestones Nanoscope Therapeutics intends to achieve over the next year[Listen Now]

In this enlightening episode, Ryan engages in a deep conversation with Dr. Paul Hutson, PharmD, a renowned researcher in the field of psilocybin and director of the Transdisciplinary Center for Research in Psychoactive Substances at the University of Wisconsin Madison. Dr. Hutson shares his extensive knowledge and insights into the promising role of psilocybin in the treatment of depression and substance use disorder.  Throughout the discussion, they delve into the research that supports the use of psilocybin in medical therapy, shedding light on the rigorous processes involved in conducting such studies. Dr. Hutson elucidates the efficacy and safety findings that have emerged from his and others research, offering listeners a glimpse into the potential future of psilocybin in mainstream medical practices. Listeners will gain a deeper understanding of the meticulous approach to research that ensures both safety and effectiveness. Dr. Hutson shares firsthand experiences and observations, providing a rich and detailed perspective on the current state of psilocybin research. Moreover, the conversation ventures into the practical aspects of integrating psilocybin into contemporary medical practices, discussing the potential frameworks and guidelines that would govern its use. They explore what the future might hold for patients and practitioners alike as they stand on the cusp of a revolutionary shift in mental health treatment.Whether you're a healthcare professional keen on the latest developments in medical research or someone interested in the evolving landscape of mental health treatment, this episode promises to be a rich source of information and insight. Tune in to be informed and to foster a deeper understanding of the promising horizon that psilocybin research is unveiling in the medical community.Biography for Dr. Paul Hutson PharmDTransdisciplinary Center for Research in Psychoactive SubstancesDr Hutson's PublicationsSingle Dose Psilocybin for Major Depression- JAMA 2023Psilocybin and QTc in healthy volunteersMeta-Analysis of research supporting Psilocybin use in anxiety and depressionPharmacokinetics of PsilocybinSubjective effects of high dose PsilocybinOther referenced studiesSingle dose psilocybin for treatment resistant depression Psilocybin for alcohol use disorderPsilocybin for For tobacco cessation

Episode Highlights With PriyankaHow her own health journey led to her helping women with health using her background in the data world Why were women not included in clinical research until 1993, and why are women diagnosed years later than men for the same conditionsHow to actually make the best use of data that we now have access toVaginal discomfort is the leading reason women seek medical help in the USAt any given moment, 30% of women have some form of vaginal dysbiosis The reason the vagina is meant to be acidic What her data set on the vaginal microbiome is showing and what we can learn from itThe most common vaginal dysbiosis and what we can learn from it84% of people with vaginal dysbiosis have no symptoms and get no treatment66% of people who have a yeast infection actually have something elseThe role sex plays in the vaginal microbiome What boric acid is and the real data on the research hereDo vaginal probiotics work? And what to know about themHow vaginal health affects fertility, pregnancy, and birth and what to know to optimize thisResources We MentionEvvyInvisible Women by Caroline Criado Perez

DOT - Use the Code DENTALDIGEST for 10% off olsenna.com Olsen Facebook Olsen Instagram Olsen Linkedin Olsen Youtube https://www.oneplacecapital.com/ Follow @dental_digest_podcast Instagram Follow @dr.melissa_seibert on Instagram Connect with Melissa on Linkedin Dr. Peter Milgrom is Professor of Oral Health Sciences and Pediatric Dentistry in the School of Dentistry and adjunct Professor of Health Services in the School of Public Health at the University of Washington. He directs the Northwest Center to Reduce Oral Health Disparities. He holds academic appointments at Case Western University, University of Rochester, and University of California, San Francisco. He maintains a dental practice limited to the care of fearful patients and served as Director of the UW Dental Fears Research Clinic. Dr. Milgrom's work includes research on xylitol, the effectiveness of fluoride varnish and iodine in preschoolers, clinical efficacy and safety of diammine silver fluoride, motivational strategies to increase perinatal and well child dental visits in rural communities, and studies of cognitive interventions in pediatric and adult dental fear. The NIH, Maternal and Child Health Bureau, HRSA, and the Robert Wood Johnson Foundation support his work. Dr. Milgrom is author of 5 books and over 300 scientific articles. His latest book, Treating Fearful Dental Patients, was published in 2009.   Dr. Milgrom was Distinguished Dental Behavioral Scientist of the International Association for Dental Research for 1999. In 1999, and again in 2000, his work was recognized by the Giddon Award for research in the behavioral sciences in Dentistry. He received the Barrows Milk Award from IADR in 2000, recognizing his work for public health including the development of the Access to Baby and Child Dentistry (ABCD) program in Washington State. In 2003, Dr. Milgrom received a Special Commendation Award from the National Legal Aid and Defenders Association and the University of Washington Medical Center Martin Luther King, Jr. Community Service Award. In 2010, he received the Aubrey Sheiham Research Award for his work on xylitol. He serves on scientific review committees for the NIDCR, NIMHHD, NINDS, Center for Scientific Review at NIH and as a consultant to the FDA. In 2005, Dr. Milgrom was appointed the SAAD Visiting Professor of Pain and Anxiety Control at the King's College Dental Institute, University of London, UK for a six-year term. In 2008 he was awarded the degree of Doctor Honoris Causa from the University of Bergen, Norway in recognition of his work in social and behavioral dentistry. In 2012, he received the University of California, San Francisco Dental Alumni Gold Medal for his contributions to Dentistry. In 2012 he was also awarded the Norton Ross Award for Excellence in Clinical Research by the American Dental Association. In 2013, he was appointed to the Council of Scientific Affairs of the American Dental Association. In 2014, he received the Irwin M. Mandel Distinguished Mentor Award from the IADR. In 2015, he served as HMDP Expert in Dental Public Health for the Singapore Ministry of Health. Dr. Milgrom received his DDS from the University of California, San Francisco in 1972 and had a previous position at the National Academy of Sciences, Engineering, and Medicine. In the last few years, Dr. Milgrom has spoken to dental associations in Argentina, Colombia, Peru, Philippines, and USA and at major universities in USA and abroad.

Dr. Nadine Spring, PhD is Founder and Director of Operations at SpringWell360. She is an enthusiastic and results-driven clinical research, public health, and wellness professional with a proven record of orchestrating health and wellness programs, community health initiatives, clinical trials, and research projects. She conferred a Bachelor of Biology at the University of Bridgeport, then went on to get a Master of Public Health and a Master of Science in Clinical Research at Icahn School of Medicine at Mount Sinai. She later got her PhD in Public Health from Walden University. Dr. Nadine Spring, PhD on LinkedIn: https://www.linkedin.com/in/nadinespring/Join my 800+ member email blasts: http://thephmillennial.com/signupThe Public Health Millennial on LinkedIn: https://www.linkedin.com/company/thephmillennial/ Omari on LinkedIn: https://www.linkedin.com/in/omari-richins-mph/Support The Public Health Millennial: https://ko-fi.com/thephmillennialChapters:@0:00 Episode Teaser@1:40 Dr. Nadine Spring, PhD Intro@4:00 Identify & personal background @6:20 Integrate wellness into public health@8:00 Research & Community Engagement@11:20 What is public health?@12:00 Health in Trinidad to USA@15:30 Bachelors in Biology at University of Bridgeport@18:50 Experiences during undergrad@26:10 Master of Public Health at Mount Sinai School of Medicine @28:30 Experiences during MPH@31:00 Work after MPH@36:30 Master of Clinical Research at Mount Sinai School of Medicine@37:22 How to get more Black people into clinical trials @41:00 Director of Clinical Research Services at Emory University@45:20 Project Director Research Centers in Minority Institutions at Morehouse @48:00 PhD in Public Health at Walden University @55:40 Experiences during MPH@58:30 Founder SpringWell360 LLC@1:01:45 Future Predictions & Connect @1:03:20 Future Predictions @1:07:20 Support The Public Health MillennialSupport the showThanks for tuning in. Let's all work together towards a culture of health, wellbeing, and equity for all. ⭐⭐ SUBSCRIBE & Leave a 5-STAR REVIEW! ⭐⭐ Follow & Support:- Contribute to the show (one-time or monthly)- The Public Health Millennial on IG - The Public Health Millennial on LinkedIn - The Public Health Millennial Website- Omari Richins, MPH on LinkedIn- Support on The Public Health Store

No CRO Project Management Experience Should I Still Apply? Don't forget to Subscribe for new content! Merch: https://teespring.com/stores/elite-cl... Subscribe:    / eliteclinicalresearch   Email: eliteclinicalgroup@gmail.com Podcast: https://anchor.fm/clinical-research-p... Steemit: https://steemit.com/@ecrgmedia Advertise: eliteclinicalgroup@gmail.com Watch: » Industry News: https://goo.gl/fNXpQ5 » All Videos: https://goo.gl/87XEFW » Interview Recaps: https://goo.gl/wJsk6W » Glassdoor Reviews: https://goo.gl/AbQzqe We do: » Insider Interviews » Resume Reviews » Question and Answer » Discuss all things Clinical Research » News and Product Reviews » Education ------------------------------------------------------------------------------------------------------------ Elite Clinical Research Group or ECRG for short is a content creating conglomerate that offers many services to individuals in the clinical research and pharmaceutical space. We always keep our "Why" of improving patients lives in mind with everything we do and are always looking to partner with people that are of like mind. Clinical Research is one of the hottest fields in the world right now and thousands of college graduates, masters candidates and phd graduates are looking to enter the clinical research world. Reach out by comment or email if we can help in any way. --- Send in a voice message: https://podcasters.spotify.com/pod/show/clinical-research-podcast/message

In a world where the demand for qualified research professionals is on the rise, training programs play a pivotal role in expanding and diversifying the talent pool. Kunal D. Patel,  Medical Director at iheed, will shed light on their recently launched Master of Science in Clinical Research program and how training programs are helping expand the clinical research workforce. 

DOT - Use the Code DENTALDIGEST for 10% off olsenna.com Olsen Facebook Olsen Instagram Olsen Linkedin Olsen Youtube https://www.oneplacecapital.com/ Follow @dental_digest_podcast Instagram Follow @dr.melissa_seibert on Instagram Connect with Melissa on Linkedin Dr. Peter Milgrom is Professor of Oral Health Sciences and Pediatric Dentistry in the School of Dentistry and adjunct Professor of Health Services in the School of Public Health at the University of Washington. He directs the Northwest Center to Reduce Oral Health Disparities. He holds academic appointments at Case Western University, University of Rochester, and University of California, San Francisco. He maintains a dental practice limited to the care of fearful patients and served as Director of the UW Dental Fears Research Clinic. Dr. Milgrom's work includes research on xylitol, the effectiveness of fluoride varnish and iodine in preschoolers, clinical efficacy and safety of diammine silver fluoride, motivational strategies to increase perinatal and well child dental visits in rural communities, and studies of cognitive interventions in pediatric and adult dental fear. The NIH, Maternal and Child Health Bureau, HRSA, and the Robert Wood Johnson Foundation support his work. Dr. Milgrom is author of 5 books and over 300 scientific articles. His latest book, Treating Fearful Dental Patients, was published in 2009.   Dr. Milgrom was Distinguished Dental Behavioral Scientist of the International Association for Dental Research for 1999. In 1999, and again in 2000, his work was recognized by the Giddon Award for research in the behavioral sciences in Dentistry. He received the Barrows Milk Award from IADR in 2000, recognizing his work for public health including the development of the Access to Baby and Child Dentistry (ABCD) program in Washington State. In 2003, Dr. Milgrom received a Special Commendation Award from the National Legal Aid and Defenders Association and the University of Washington Medical Center Martin Luther King, Jr. Community Service Award. In 2010, he received the Aubrey Sheiham Research Award for his work on xylitol. He serves on scientific review committees for the NIDCR, NIMHHD, NINDS, Center for Scientific Review at NIH and as a consultant to the FDA. In 2005, Dr. Milgrom was appointed the SAAD Visiting Professor of Pain and Anxiety Control at the King's College Dental Institute, University of London, UK for a six-year term. In 2008 he was awarded the degree of Doctor Honoris Causa from the University of Bergen, Norway in recognition of his work in social and behavioral dentistry. In 2012, he received the University of California, San Francisco Dental Alumni Gold Medal for his contributions to Dentistry. In 2012 he was also awarded the Norton Ross Award for Excellence in Clinical Research by the American Dental Association. In 2013, he was appointed to the Council of Scientific Affairs of the American Dental Association. In 2014, he received the Irwin M. Mandel Distinguished Mentor Award from the IADR. In 2015, he served as HMDP Expert in Dental Public Health for the Singapore Ministry of Health. Dr. Milgrom received his DDS from the University of California, San Francisco in 1972 and had a previous position at the National Academy of Sciences, Engineering, and Medicine. In the last few years, Dr. Milgrom has spoken to dental associations in Argentina, Colombia, Peru, Philippines, and USA and at major universities in USA and abroad.

Clinical research has been around for over 300 years. Todd Nicklas explains why it still isn't perfect but still offers benefits for patients and healthcare providers to Jim Cagliostro.    Episode Introduction  Todd explains the history of clinical research through Paul Offit's You Bet Your Life, asks the big question of ‘'replacement or supplement'', and explains why patients are always their own biggest advocates. He also explains the need for monitoring the ‘'gray line'', and why the key focus in all clinical trials is failing early.   Show Topics   Clinical research isn't always the answer for patients  Supplement or replace? The big question for balance Handling complexities in replacing medication  The high cost of getting drugs to market  Focus on failing early  Patient benefits: a case study with Camzyos Teamwork helps the growth process   03:35 Clinical research isn't always the answer for patients  Todd highlighted the importance of a balanced view in clinical research, highlighting ‘'You Bet Your Life'' by Paul Offit.  ‘'So I kind of wanted to start out with that sometimes it is the answer, clinical research for a patient, or sometimes it's not the answer.. I appreciate reading a book by Paul Offit called You Bet Your Life. And ..he went through the past few hundred years in some of the early medical interventions in development and when they were very early starting off, the first blood transfusions that were tried or first types of anesthesia. And when he would dive into those stories, I mean, Jim, there were dangerous approaches. We look back today, really wild, crazy ideas or people died or people had maimed arms and legs from radiology exposure and such, but it leads us to where we are today with radiology procedures and blood donation and transfusions and anesthesia. Just a few examples. He did a few others…So his approach was, there's a point, and maybe we'll get to this later, where you can kind of know where the risks are worked out, but you can't just write it off and throw the baby out with the bath water. There might be something still good here that we need to learn. And so sometimes it could be the answer like, look where anesthesia and blood donation is today. But sometimes it's not the answer. You can look back for the past few hundred years and health authority figures or people at various companies thought that lobotomies were a good idea or sterilizing the mentally ill or bloodletting. You can look at some of these things that today we'd say, yeah, they were dangerous or inappropriate or not what they were intending to. So people can be wrong and people can be right. And so you have to understand that balance first and foremost. I kind of wanted to stress that upfront.''   06:01 Supplement or replace? The big question for balance Todd explained why this question is essential to balance in patient trials.  ‘'But I think the two questions you have to ask when you're trying to balance it is first, does the present, shall I say medication or intervention, does it supplement what is presently trying to treat or help my disease or does it replace the present? And the reason I wanted to lead with that or categorize that is because when I was a research nurse for many years in the hospital, you're working with sometimes doctors that really love the research that you're doing and are an investigator with that research. Some doctors could care less and tell you to go away and say, "Don't bother me. Really, you're going to bother me with this research?" Some doctors might have no clue because they're not even connected with your hospital system. And so how do you interact with doctors A, B, and C that I just gave as examples because you're going to have to approach them differently? I think that's probably self-evident. So you have to say, "Well, listen, it's meant to supplement and here's how it could work already with the present medical regimen that these patients are getting or it's meant to replace the treatment and this is why and this is how you should manage them." So I guess first, does it supplement the present treatment? This is I guess a question that research has to answer: how does the present treatment alone that they're already on affect a certain lab level or a MRI scan or a vital sign that might be concerned about your blood pressure or what have you, versus how much does it affect that measurable point with the two together or the research medication or intervention? We get a lot of time to dive into that, but I just want to leave that hanging out there to think about that.''   10:08 Handling complexities in replacing medication  Todd emphasized the need for clarity with patients, hospitals and in documentation in ‘'replacement'' trials.  ‘'When you're intending to replace the present treatment, well, then the doctors will say, "Well, wait a minute. When does that happen? Is there a washout period? What's the half-life of the drug that they're presently taking and the one that you want them to take in the research study? How quickly can it come on board and give a therapeutic benefit?" These questions, like I said before with the previous point, you need to be very careful in how you convey that to the patient, to the doctors, to the nurse practitioners, how it's in the documentation. Things can get forgotten, as you know. So it has to be clear in the documentation as well. You and I worked with LVADs, which are the heart pump devices. Could it replace their heart failure meds across the board? Maybe. If they have a really great response, maybe you can get rid of a good bit of them. And then the doctor would say, "Well, when would that occur? And how do we do that in the hospital?" So there are tough questions to ask and you might say... Oh, sorry, I forgot to mention this to you with the supplement. These studies are often with supplements, placebo controlled. Well, how do I handle... If I'm not supposed to know if they're on placebo or not, but it could supplement and have some impact, what do I watch for? What blood levels do I keep an eye on? But with replacement, that doesn't typically happen because they need a therapy, they need to be treated for something. So you have to either be getting the old medication or the research medication. It's not as much. So I wanted to mention that real briefly too, but that is another point I wanted to get across.''   15:10 The high cost of getting drugs to market  ‘'Jim, let's say you have a compound, an asset, a drug for your company, and it looks like it could affect a therapeutic area or a disease process that could pull in two million in sales and another avenue that might pull in two billion in sales. Some people might be more led to the two billion regardless of everything else. So I respect that. However, you have to keep in mind, so I've acknowledged that there is some negative approaches to things that are not good and can be shady, but at the same time, research, if you're not in the space, it takes so much money to get a drug approved in the United States with the FDA because the FDA is very careful with understanding all the components that need to be in place and the data that needs to be understood to say this medication should be on the market….. the typical cost to develop a drug is $2 billion on average. And the average time it takes from saying, "Here's our asset in preclinical," which is kind of working with animals and such, to the time it gets approved is about 13 and a half or 14 years.''   19:34 Focus on failing early Todd said that failing early would save costs further down the line.  ‘'Because the big focus today, and I think I might've mentioned the last podcast, is to fail early. So what a lot of companies like to do is to do a lot of high throughput, testing thousands of different compounds and various disease processes and targets in the body to understand where they might fail down the road, and there's amazing technology to figure that out, so they can hopefully pick the right one to go down that rabbit hole, shall we say, and hopefully get an approval because we know-it's such a big investment. And, oh, I didn't say this, but I think a compound, once it first gets found to get FDA approved through all the phase ones, twos and threes, it's like 5% or 10%, something really low. Even if things sound really appealing, the amount of drugs that actually get approved after all these things, we talked $2 billion, 13 and a half years, is still pretty small. Because the FDA is trying to be careful, they want to make sure something's safe and effective, that's the big thing. And it is great that we have both of those things that are important. You don't want something that's just one of those things, I mean safe but not effective, or effective but not safe. I mean both of those don't sound appealing to the modern consumer.''   31:35 Patient benefits: a case study with Camzyos Todd provided an example of how individuals can benefit from research.  ‘'This is probably six, seven years ago now. I did a study with what's now Camzyos, or mavacamten, a BMS drug, and it helps patients that have hypertrophic cardiomyopathy, apologies if I used this last time, but I don't think I did, where it is an overdevelopment of the muscles of the heart to the point that it's typically pushing into the left ventricular outflow tract, which is the exiting tunnel, shall we say, out to the aorta, which goes to the rest of your body and provides blood to the rest of your body. So the muscle as it pushes into that area, it makes the opening smaller and smaller so less blood can go out to the rest of your body to provide blood to your tissues and organs. And at the point that we were doing the study, the only fixes or treatment were either surgery to cut down that muscle or beta blockers and things to reduce the blood pressure that maybe reduces pressure in that area, but those are difficult to really target long-term or even midterm. It does affect the small muscle fibers and you actually see a reduction in that muscle area. So the reason I say this is because I had a patient that did this and it was a very involved, I think it was early Phase 1b or 2a, pretty early on study where he had to come in weekly for 12 weeks and do echoes and MRIs and a lot of blood work. And some of the visits I remember with him, he was in his 20s, were maybe three, four or five hours long, very busy visits for sure. So the question is, I mean, he's a young kid, does he want to have this burden on his life to do all this? He had a good relationship with the physicians there that saw him, and I think that he really thought this could help him prevent downstream problems or give him a few years before that muscle was impacting enough that he might need surgery or what have you. So it was certainly his decision and it was inconvenient, like I said, those visits and such. But he had good results and I was able to, I believe it was actually open label, so I kind of got to see how things were going from his echoes and data and such. But even within the first week or two, we saw really impressive results from him.''   36:41 Teamwork helps the growth process Todd said delegation prevents people from working in silos.  ‘'And I think that what I'm getting at is good delegation is not a negative thing and it doesn't reflect like you don't know what you're doing. I think we as human beings feel like, "Oh, I'm delegating so I clearly don't want to learn that, or I'm not good enough versus someone else." But no, what I found is, and especially now in larger pharmaceutical companies where there's a lot of team members, it's really beneficial to say, "Hey, you're really good at X, you're really good at Y. I should know them a little bit, and I do, and I oversee that, whatever, but I'm not going to jump in. I'm going to let you do it. Can you get back to me in a certain timeframe? Can you help me with this? Can you help me with that?"' It's very beneficial because not only do you kind of know the lines in the sand where people are working and not working, you're respecting your skillset and theirs, and you're working together as a team rather than like, I'm in my own silo. I'm not going to look both ways. I am my own person. I found that to be really, really helpful, and you can learn a lot at the same time. It really helps you learn a lot more than just saying, "I'll do my own thing." I mean, yeah, you might be baptized by fire and learn it kind of, but you might learn it a wrong way, actually. So I think that's probably what I would say and what I've really appreciated in my growth process.''   Connect with Lisa Miller on LinkedIn Connect with Jim Cagliostro on LinkedIn Connect with Todd Nicklas on LinkedIn Check out VIE Healthcare and SpendMend    You'll also hear:    The longevity of clinical research, starting with James Lind in 1747. ‘'We can't avoid research. We've been using the clinical research approach for the past 300 or so years….and then there were some studies that you can go back to even in the 1500s, that people would try various things to see what worked better than others.''   Patients don't live in a health vacuum: ‘'…..every patient you have is not going to be in a vacuum and have one disease and have nothing else. They're going to be 80 years old, they're going to have 10 other medications they're taking or four other disease processes that are going on. You need to know what's on board, what's working, what's not working.''   Why the patient is the biggest advocate: ‘'..the thing I really appreciated most was telling the patients the nitty-gritty and really driving home the educational points because then they are there with doctors B and C that might not know or want to be involved in the study and they can say, "Wait, wait, hold up. Don't do this. Or maybe talk to Todd first because this might affect that."    Monitoring the ‘'gray line'' in patient trials: ‘'Because some cancer patients do very early phase one and twos because they have to because of the development process or because of their cancer diagnosis or what have you, you might have to do early on. But are we past that line? Are we not? And what might that line look like? And that's why consent forms nowadays are extremely long because patients have to read all the safety data.''   What To Do Next:   Subscribe to The Economics of Healthcare and receive a special report on 15 Effective Cost Savings Strategies.   There are three ways to work with VIE Healthcare:   Benchmark a vendor contract – either an existing contract or a new agreement. We can support your team with their cost savings initiatives to add resources and expertise. We set a bold cost savings goal and work together to achieve it.  VIE can perform a cost savings opportunity assessment. We dig deep into all of your spend and uncover unique areas of cost savings.  If you are interested in learning more, the quickest way to get your questions answered is to speak with Lisa Miller at lmiller@spendmend.com or directly at 732-319-5700.  

To apply for the ACA Healthcare Policy Fellowship - Visit the ACA members section and go to the volunteer opportunities link: https://www.acatoday.org/wp-content/uploads/2023/08/Syllabus.pdfDr. Kris Anderson graduated from Palmer College of Chiropractic's Davenport campus with his DC degree in 2007. He followed that with a master's Fellowship in Clinical Research at the Palmer Center for Chiropractic Research, where he attained his MS degree in 2010. In 2012, Dr. Anderson joined his wife, Dr. Stacy Hallgren, in her practice in Grand Forks, ND, and they continue to operate Performance Chiropractic together. In 2018, Dr. Anderson began work with Valley Community Health Center, now Spectra Health, a Federally Qualified Health Center (FQHC) and Patient-Centered Medical Home (PCMH), to add chiropractic services to their scope of practice. He became their first DC, splitting his time between private practice and Spectra Health. In his role with Spectra Health, he continues seeking new treatment pathways for underserved communities, those who typically lack access to chiropractic services, and especially those in non-traditional living environments or treatment programs for substance use or other disorders.Beyond patient care, Dr. Anderson serves the chiropractic profession in multiple other ways. He has been a board member of the ND Chiropractic Association (NDCA), including serving as president from 2019-2021, and continues to represent the NDCA in various ways as the Insurance Liaison. He was honored as the NDCA Chiropractor of the Year in 2019. Dr. Anderson has twice served on the State of ND Board of Chiropractic Examiners' subcommittees to draft rules and regulations for the Chiropractic Practice Act, once for dry needling and the other for certified chiropractic clinical assistants. Additionally, Dr. Anderson has been a member of the Clinical Compass Board since 2018, now serving as Vice-Chair. Since 2019, Dr. Anderson has represented the ACA as the Advisor for the American Medical Association (AMA)/Specialty Society Relative Value Scale Update Committee (RUC) Healthcare Professionals Advisory Committee (HCPAC). His experience in health policy has led to opportunities to represent the profession at national meetings convened by organizations such as CMS and PCORI. He currently serves as Vice-Chair of the ACA Health Policy and Advocacy Commission and serves multiple subcommittees as either chair or member. He became the House of Delegates Alternate Delegate for ND in 2022 and is a member of the ACA Governors Advisory Cabinet (GAC) and the ACA-PAC Capitol Club. In addition to the NDCA, Clinical Compass, and ACA, Dr. Anderson is a member of the World Federation of Chiropractic (WFC), the North American Spine Society (NASS), the American Public Health Association (APHA), and the National Strength and Conditioning Association (NSCA) where he maintains an active supporting credential as a Certified Strength and Conditioning Specialist (CSCS). He is also a Certified Medical Examiner.Dr. Anderson's commitment to research has followed him from his fellowship into his practice setting. He maintains an ongoing collaboration with colleagues at multiple chiropractic institutions, which has resulted in multiple publications and posters at research conferences. He has contributed to public health with work with the ND State University School of Nursing on a tobacco cessation project and as a grantee of the ND Department of Health to improve hypertension and pre-diabetes identification and management in chiropractic practice. He is also a peer reviewer.Dr. Anderson and his wife, Stacy, have four children and live on a small hobby ranch in rural Grand Forks County, ND. They are members of their local Lions Club International Chapter and serve their community in various other ways as well, such as church council and coaching youth sports. They enjoy spending time with family, working on their hobby ranch with their many animals, camping, and being outdoors as much as possible.

What do you think about diversity, equity, and inclusion? How do you feel about what is going on currently?   In this segment, Dr. Ravi Iyer discusses going beyond the cliche which is typically around color, gender, or orientation. Which allows DEI as metric of Health in a Society.       WHO IS DR. RAVI? Physician-scientist, inventor, author, and entrepreneur, Dr Iyer is a trans-disciplinary polymath who has traveled from the medical colleges on the banks of the Ganges to the rarefied ivory towers of Harvard Medical School. He has been a Hospice director, and hospital chairman, the founder of the Iyer Clinic, and the Director of Clinical Research of a medical group.   His extensive background of over 40 years in the fields of medicine and science, and deep insight into the human condition puts him in a unique position to speak about these issues with clarity, incisive depth, and deep compassion.       DR. RAVI'S CALL TO ACTION Check out my book The Reaper's Dance: 1000 Days of COVID on Amazon for more insights on leadership and caring under crisis & follow me on my Linktree at https://linktr.ee/driyermd.  @driyermd        CALL TO ACTION Subscribe / Follow GEMS with Genesis Amaris Kemp podcast & YouTube channel, Hit the notifications bell so you don't miss any content, and share with family/friends.   GENESIS'S INFO https://genesisamariskemp.net/genesisamariskemp     If you would like to be a SPONSOR or have any of your merchandise mentioned please reach out via email --- Send in a voice message: https://podcasters.spotify.com/pod/show/genesis-amaris-kemp/message Support this podcast: https://podcasters.spotify.com/pod/show/genesis-amaris-kemp/support

Food allergies have risen in the United States over the last few decades. Research suggests that 40 years ago the actual prevalence of food allergies was less than 1%. But this year, the Centers for Disease Control and Prevention (CDC) released data showing that almost 6% of U.S. adults and children have a food allergy. But this trend is not present in all countries — and what people are allergic to varies globally. Today, we dive into the complex world of food allergies with Dr. Waheeda Samady. She's the Director of Clinical Research at Northwestern University's Center for Food Allergy and Asthma Research.Have a science question? Email us at shortwave@npr.org.

HOUR 3 Christine Duncan, Medical Director of Clinical Research, Boston Children's Governor Maura Healy joins, talks about trying to lower the cost of living in Massachusetts Sean Flaherty from Keches Law joins, talks about "Keches Cares" campaign

Glenna Mauldin, DVM, MS, Diplomate ACVIM (Oncology and Nutrition), and her team provide guidance and support for clinical research activities within Thrive Pet Healthcare, including research project design, execution, standards, and regulations. Dr Mauldin received her Doctor of Veterinary Medicine from the Western College of Veterinary Medicine, Saskatoon, Saskatchewan, Canada. She completed a rotating internship and residency in medical oncology at The Animal Medical Center in New York, and a residency and master's degree in nutrition at Cornell University in Ithaca, New York. She is board certified by the American College of Veterinary Internal Medicine in both oncology and nutrition. Before joining Thrive Pet Healthcare in early 2022, Dr Mauldin was Director of Clinical Research for PetCure Oncology. She has practiced veterinary medical oncology and nutrition for over 30 years in both private practice and academic settings, including The Animal Medical Center in New York, Louisiana State University in Baton Rouge, Louisiana, and VCA Western Veterinary Specialist and Emergency Centre in Calgary, Alberta, Canada. Dr Mauldin has authored over 75 peer reviewed publications, book chapters, and scientific abstracts. She lectures frequently at regional, national, and international meetings.

Are you curious about the important work taking place inside the Veterans Affairs (VA) Healthcare system?  Are you interested in learning more about melanoma epidemiology and clinical research?  Then you don't want to miss this episode with our very special guest, Dr. Rebecca Hartman.  

Best Clinical Research Jobs Don't forget to Subscribe for new content! Merch: https://teespring.com/stores/elite-cl... Subscribe:    / eliteclinicalresearch   Email: eliteclinicalgroup@gmail.com Podcast: https://anchor.fm/clinical-research-p... Steemit: https://steemit.com/@ecrgmedia Advertise: eliteclinicalgroup@gmail.com Watch: » Industry News: https://goo.gl/fNXpQ5 » All Videos: https://goo.gl/87XEFW » Interview Recaps: https://goo.gl/wJsk6W » Glassdoor Reviews: https://goo.gl/AbQzqe We do: » Insider Interviews » Resume Reviews » Question and Answer » Discuss all things Clinical Research » News and Product Reviews » Education ------------------------------------------------------------------------------------------------------------ Elite Clinical Research Group or ECRG for short is a content creating conglomerate that offers many services to individuals in the clinical research and pharmaceutical space. We always keep our "Why" of improving patients lives in mind with everything we do and are always looking to partner with people that are of like mind. Clinical Research is one of the hottest fields in the world right now and thousands of college graduates, masters candidates and phd graduates are looking to enter the clinical research world. Reach out by comment or email if we can help in any way --- Send in a voice message: https://podcasters.spotify.com/pod/show/clinical-research-podcast/message

Unlike an electrical engineer or a plumber, clinical research roles are not explicitly defined or categorized as such, in government employment databases. There are no certification or degree requirements to work as a clinical research professional either. To explore the topic of clinical research as a profession, I invited Erike Stevens on the podcast. Erika advises life sciences, academic medical centers, hospitals, cancer centers, foundations and health systems process improvement initiatives for productivity, quality and efficiency in operations, cross-functional relationships, administration, manufacturing, and compliance.  She has over 20 years of research/ R&D experience, serving in roles such as Vice President Research, Senior Managing Director, Director Clinical Trials Office, Director of Clinical Research, Interim Executive Director, Clinical Trials Office and Director of Research Operations.  Erika holds her B.A. from the University of Vermont, her M.A. from Case Western Reserve University and her M.A. from Temple University.  She also holds a Graduate Certificate in Gerontology from Case Western University. Please join me in welcoming Erika on the show. Podcast Sponsor(s): This podcast is brought to you by Slope. Slope drives operational excellence for highly complex, sample-intensive, early-phase clinical trials. The platform transforms chaotic clinical trial supply chains into protocol-specific operational workflows for sponsors, CROs, clinical research sites and labs. Slope is trusted by industry leaders in complex early-phase clinical trials from top 50 pharma and CROs to emerging biotechs, and a global site network including NCI cancer centers and AMCs. Learn more at https://www.slopeclinical.com/ This podcast is brought to you by Veeva. Veeva connects patients, sites, and sponsors, on a single technology ecosystem to make clinical trials easier and faster. I'm particularly excited about Veeva SiteVault. SiteVault gives research sites one place to work with sponsors – to reduce the number of systems and logins used to run clinical trials. To learn more, visit https://sites.veeva.com/.  

In this episode of the Brawn Body Podcast, Dan is joined by Dr. Joseph "Jake" O'Neil from Rothman Orthopaedic Institute to discuss compartment syndrome, including examination, evaluation, diagnosis, surgical management, and rehab considerations. Dr. O'Neil is a board certified, orthopaedic surgeon specializing in the treatment of foot and ankle disorders.  He completed his residency in Orthopaedic Surgery at Thomas Jefferson University Hospital in Philadelphia, PA.  He then completed a fellowship in Foot and Ankle Surgery at MedStar Union Memorial Hospital in Baltimore, MD. Dr. O'Neil has authored numerous research publications and serves as the Director of Clinical Research for the Foot and Ankle Division here at Rothman Orthopaedics.  In addition, he has lectured and presented his research at national meetings.  He is a member of the American Academy of Orthopaedic Surgeons as well as the American Orthopaedic Foot and Ankle Society.  He treats all foot and ankle conditions and has particular interests in acute fractures of the foot and ankle, sports-related injuries, ankle arthroscopy, arthritis of the foot and ankle, ligament and tendon repair/reconstruction, bunions, hammertoes, complex deformity and total ankle replacement.  For more on Dr. O'Neil, be sure to check out https://rothmanortho.com/physicians/joseph-t-oneil-md Episode Sponsors: MoboBoard: BRAWNBODY10 saves 10% at checkout! AliRx: DBraunRx = 20% off at checkout! https://alirx.health/ MedBridge: https://www.medbridgeeducation.com/brawn-body-training or Coupon Code "BRAWN" for 40% off your annual subscription! CTM Band: https://ctm.band/collections/ctm-band coupon code "BRAWN10" = 10% off! PurMotion: "brawn" = 10% off!! TRX: trxtraining.com coupon code "TRX20BRAWN" = 20% off GOT ROM: https://www.gotrom.com/a/3083/5X9xTi8k Red Light Therapy through Hooga Health: hoogahealth.com coupon code "brawn" = 12% off Ice shaker affiliate link: https://www.iceshaker.com?sca_ref=1520881.zOJLysQzKe Training Mask: "BRAWN" = 20% off at checkout https://www.trainingmask.com?sca_ref=2486863.iestbx9x1n Make sure you SHARE this episode with a friend who could benefit from the information we shared! Check out everything Dan is up to, including blog posts, fitness programs, and more by clicking here: https://linktr.ee/brawnbodytraining Liked this episode? Leave a 5-star review on your favorite podcast platform --- Send in a voice message: https://podcasters.spotify.com/pod/show/daniel-braun/message Support this podcast: https://podcasters.spotify.com/pod/show/daniel-braun/support

What if you could uncover the truth about clinical research and its impact on medical treatment? We have the answers in this week's MedEvidence Monday Minute Radio Show. Join Kevin Geddings, alongside our knowledgeable medical expert, Dr. Michael Koren, for a riveting discussion about the reality of clinical research. We delve into the intricacies of a powerful new class of drugs, in particular, Ozempic or Semaglutide, commonly used for diabetes but with far-reaching benefits for obesity, heart disease, and metabolic syndrome sufferers. Dr. Koren enlightens us with the facts behind these game-changing medical studies, debunking misconceptions and highlighting the importance of fact over opinion in the field of clinical research. He emphasizes that the results are backed by solid data gathered from thousands of patients, not just professional sentiments. Discover how drugs like Ozempic are changing lives and reshaping our understanding of medical treatment. Be part of this enlightening dialogue that will challenge how you perceive medical research and treatment. Settle in for a stimulating discussion and get ready to learn about the truth behind the data in medicine and health care.Be a part of advancing science by participating in clinical researchShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramTwitterLinkedIn Powered by ENCORE Research GroupMusic: Storyblocks - Corporate InspiredThank you for listening!

2023 Guide to landing a Clinical Research Job Don't forget to Subscribe for new content! Merch: https://teespring.com/stores/elite-cl... Subscribe:    / eliteclinicalresearch   Email: eliteclinicalgroup@gmail.com Podcast: https://anchor.fm/clinical-research-p... Steemit: https://steemit.com/@ecrgmedia Advertise: eliteclinicalgroup@gmail.com Watch: » Industry News: https://goo.gl/fNXpQ5 » All Videos: https://goo.gl/87XEFW » Interview Recaps: https://goo.gl/wJsk6W » Glassdoor Reviews: https://goo.gl/AbQzqe We do: » Insider Interviews » Resume Reviews » Question and Answer » Discuss all things Clinical Research » News and Product Reviews » Education ------------------------------------------------------------------------------------------------------------ Elite Clinical Research Group or ECRG for short is a content creating conglomerate that offers many services to individuals in the clinical research and pharmaceutical space. We always keep our "Why" of improving patients lives in mind with everything we do and are always looking to partner with people that are of like mind. Clinical Research is one of the hottest fields in the world right now and thousands of college graduates, masters candidates and phd graduates are looking to enter the clinical research world. Reach out by comment or email if we can help in any way. --- Send in a voice message: https://podcasters.spotify.com/pod/show/clinical-research-podcast/message

Is the CRA Golden Age Over? Don't forget to Subscribe for new content! Merch: https://teespring.com/stores/elite-cl... Subscribe:    / eliteclinicalresearch   Email: eliteclinicalgroup@gmail.com Podcast: https://anchor.fm/clinical-research-p... Steemit: https://steemit.com/@ecrgmedia Advertise: eliteclinicalgroup@gmail.com Watch: » Industry News: https://goo.gl/fNXpQ5 » All Videos: https://goo.gl/87XEFW » Interview Recaps: https://goo.gl/wJsk6W » Glassdoor Reviews: https://goo.gl/AbQzqe We do: » Insider Interviews » Resume Reviews » Question and Answer » Discuss all things Clinical Research » News and Product Reviews » Education ------------------------------------------------------------------------------------------------------------ Elite Clinical Research Group or ECRG for short is a content creating conglomerate that offers many services to individuals in the clinical research and pharmaceutical space. We always keep our "Why" of improving patients lives in mind with everything we do and are always looking to partner with people that are of like mind. Clinical Research is one of the hottest fields in the world right now and thousands of college graduates, masters candidates and phd graduates are looking to enter the clinical research world. Reach out by comment or email if we can help in any way. --- Send in a voice message: https://podcasters.spotify.com/pod/show/clinical-research-podcast/message

اليوم الممرضة لمى بتشرحلنا دور منسقة البحث الاكلنيكي في المستشفيات كيف من ممرضة في قسم الباطني قدرت تاخد دا المنصب وايش مميزاته وايش المهارات المطلوبة والمهارات المكتسبة من دا التخصص وكيف كانت بتشتغل بشغف في فترة كوفيد وبتجرب مع الفريق الى ان وصلو للنتائج المطلوبة ووضحتلنا الفرص المميزة اللي ممكن تلاقوها في دا التخصصلا تنسو تتابعونا وتتفاعلو معانا على حساباتنا في تويتر وانستجرام @hallegpodcast

 DOT - Use the Code DENTALDIGEST for 10% off olsenna.com Olsen Facebook Olsen Instagram Olsen Linkedin Olsen Youtube https://www.oneplacecapital.com/ Follow @dental_digest_podcast Instagram Follow @dr.melissa_seibert on Instagram Connect with Melissa on Linkedin https://www.kokicheducation.com Dr. Kokich Jr. received his dental degree from Tufts University School of Dental Medicine in 1996 and completed a general practice residency at the University of Washington Medical Center in 1997. He remained at the University of Washington for his orthodontic training where he obtained his Masters in Orthodontics in 1999. Since then he has remained on faculty in the Department of Orthodontics as an Affiliate Assistant Professor while maintaining a private practice in Tacoma, Washington. He has received the Charles L. Pincus Research Award for Clinical Research from the American Academy of Esthetic Dentistry and his current research and publications are primarily involved with esthetic, interdisciplinary dentistry. He is a diplomate of the American Board of Orthodontists and a member of both the Angle Society and the American Academy of Esthetic Dentistry. He has written or co-written four book chapters as well as numerous scientific and review articles. Dr. Kokich Jr. has given over 240 lectures nationally and internationally on interdisciplinary dentistry and dental esthetics emphasizing comprehensive treatment planning and the importance of properly sequencing orthodontic, periodontal, and restorative treatment.

This week we're rerunning a classic Ortho Show episode from February 2, 2022 to commemorate orthopedic great Dr. Javad Parvizi's retirement. Dr. Javad Parvizi is an American Board Certified, fellowship trained, Orthopaedic Surgeon and the Director of Clinical Research at the Rothman Orthopaedic Institute.  Dr. Parvizi started at Rothman in 2003.  He holds the James Edwards Professor Chair of Orthopaedics at Thomas Jefferson University.  He specializes in the management of young patients with hip disorders such as dysplasia, femoroacetabular impingement and other complex hip and knee conditions.  He is a renowned world expert in the field of periprosthetic joint infection, joint preservation, and joint reconstruction.  Topics include: -He joined Rothman Orthopaedics in 2003 as the 13th physician and today, Rothman has over 250+ physicians. Dr. Parvizi tells us about the vision of Dr. Richard Rothman in creating Rothman Orthopedics and "private-medics," where private practice comes together with academics. -We discuss the creation of Parvizi Surgical Innovation (PSI), established in 2016, with a founding circle of 32 individuals. They follow an incubator model to evaluate innovative ideas with a product council, financing and resources. -Only two of our guests have their own Wikipedia pages and Dr. Parvizi is one of them. Check out Dr. Parvizi's page with his vast accolades and accomplishments here. -We hear about where does he think we are going in the war on bacteria and infections? -We also hear Dr. Parvizi's great wisdom on innovation. He says it simplifies life, makes it more affordable and changes status quo positively. Find out more about Dr. Parvizi here.

Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Salma Jabbour, Clinical Chief, Radiation Oncology and Vice Chair of Clinical Research & Faculty Development at RWJUH/Rutgers Cancer Institute. Together they discuss a plenary presentation that was given at ASCO 2023 on rectal cancer titled, the PROSPECT (Preoperative Radiation or Selective Preoperative Radiation and Evaluation before Chemotherapy and TME) trial. The PROSPECT trial attempts to challenge the current treatment paradigm by individualizing treatment through the use of radiotherapy selectively rather than reflexively. This is a randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for the treatment of locally advanced rectal cancer (LARC). For more information, please visit: www.CarisLifeSciences.com/POA-Intro/

The CE experience for this Podcast is powered by CMEfy - click here to reflect and earn credits: https://earnc.me/1pbG28 Dr. Johnson is a Clinical Assistant Professor of Orthopaedic Surgery specializing in Foot and Ankle disorders with an emphasis on Podiatric Surgery at the University of Michigan Medical School. Dr. Johnson completed his medical education at Kent State University College of Podiatric Medicine in Cleveland, OH. Dr. Johnson completed post-graduate Podiatric Medicine and Surgery training at HCA Florida Aventura Hospital in Miami, FL. He completed a Podiatric Clinical Research and Wound Care fellowship at Penn Medicine- University of Pennsylvania Health System in Philadelphia, PA. During his fellowship training, Dr. Johnson earned a Post-Doctoral Certificate in Clinical Research from the University of Pennsylvania Perelman School of Medicine. Dr. Johnson brings a wealth of knowledge and expertise in podiatric surgery, emphasizing wound healing and prevention. He is board certified in Podiatric Medicine by the American Board of Podiatric Medicine. In addition, Dr. Johnson is a Board-Certified Wound Care Specialist Physician by the American Board of Wound Management. Dr. Johnson serves as a Board Member of Kent State University College of Podiatric Medicine and Chairman of the Board of Directors for the American Society of Podiatric Surgeons.   Join the Conversation! We want to hear from you! Do you have additional thoughts about today's topic? Do you have your own Prescription for Success? Record a message on Speakpipe Unlock Bonus content and get the shows early on our Patreon Follow us or Subscribe: Apple Podcasts | Google Podcasts | Stitcher | Amazon  | Spotify --- Show notes at https://rxforsuccesspodcast.com/164 Report-out with comments or feedback at https://rxforsuccesspodcast.com/report Music by Ryan Jones. Find Ryan on Instagram at _ryjones_, Contact Ryan at ryjonesofficial@gmail.com Production assistance by Clawson Solutions Group, find them on the web at csolgroup.com    

Innovating Patient Recruitment: A Conversation with BBK Worldwide Founders Joan F. Bachenheimer and Bonnie A. Brescia   The Conference Forum moderates a webcast featuring Joan F. Bachenheimer and Bonnie A. Brescia, the founders of BBK Worldwide, who walk us through the evolution of patient recruitment and engagement, the connection to the women's and consumer healthcare movement, the need for changes in communication and the rise of the patient voice. They also address the impact of scientific advances on patient recruitment and the importance of preparing to meet the evolving changes. The timing of the webcast coincides with the company's 40-year anniversary.   Guests:  Joan F. Bachenheimer, Founder, Chief Executive Officer, BBK Worldwide Bonnie A. Brescia, Founder, Chief Development Officer, BBK Worldwide   Moderated by: Valerie Bowling, Executive Director, Conference Forum   For more information on BBK Worldwide, visit www.bbkworldwide.com For more information on the Conference Forum, visit www.theconferenceforum.org

Our guest in this episode is Julie Kidd, a Clinical Pharmacist with a focus on Multiple Sclerosis Clinical Care and Research. She also has past experience as a Clinical Assistant Professor and expertise in Hospital Pharmacy, Clinical Research, Medical Education, and Public Speaking, Let's dive into Julie Kidd's inspiring story and wisdom in the world of clinical pharmacy. Stay tuned for an enlightening conversation ahead!   Here are the highlights of my conversation with Julie: 03:34 - How childhood experiences can influence future career decisions. 09:24 - The coaching process, including deep-diving into the clients' interests, passions, and goals to find the right career fit. 12:59 - A client success story on how she found her dream job through coaching. 15:24 - The challenge of pharmacists wanting to get more out of their careers and breaking free from the "funk" of dissatisfaction. 19:38 - How pharmacists tend to be self-critical and how they often undervalue their skills. Alex emphasizes the importance of having a pharmacist coach who understands these challenges. 21:47 - Julie shares surprising benefits of coaching, such as clients making positive changes in their personal lives. 23:38 - How to step outside your comfort zones and create your own unique paths to success. Links mentioned in the Episode: The Happy PharmD - https://thehappypharmd.com/ We get pharmacists jobs they love! If you are ready to find your dream job and enjoy a balanced work and home life, we want to connect with you.  Click the link below to book a free call with us! https://thehappypharmd.com/HPDPodcast

Breaking The Silence with Dr Gregory Williams With, Guest Christina Reed. NP Christina an assistant professor at Baylor College of Medicine in Houston Texas. Christina is also Director of Clinical Research for the department of Obstetrics & Gynecology, & Director of operations for the Placenta Accreta Spectrum Care Team at Texas Children's Pavilion for Women & Ben Taub Hospital.

In today's episode our guest Michelina Disibio shares her own personal insights and expertise on growing your own food indoors. Michelina Disibio is a healthcare practitioner who loves to share the importance of health by choosing real food. Many of the foods we consume today have been genetically modified and riddled with pesticides that negatively impact our health causing hormonal imbalance and many other illnesses. By growing your own food as well as taking in real nutrients from a reliable source from a well-established company which our guests will explain we can greatly improve our health. A real plus that our guest will share with us is the option to not only grow our own food and help or children and grandchildren to eat healthier but there is a way to benefit and profit and earn income as well. The purpose of this episode is to educate and inform you on options available to you that not just benefits ourselves but our entire family. You can reach out to Michelina for more information by visiting here! https://www.linkedin.com/in/mdisibio/ Clinical Research https://www.juiceplus.com/us/en/learn/ingredients-and-benefits/clinical-research

Do you ever feel like your doctor isn't listening to you? You're not alone. A study published in the Journal of General Internal Medicine reveals that doctors interrupt their patients after only 11 seconds of listening. Dr. Michael Koren, flips the script and emphasizes the importance of patient listening, particularly in clinical research. In this episode of MedEvidence Monday Minute, we're not just unraveling medical myths, but also highlighting the importance of diversity in clinical research. Dr. Koren shares his experiences at a medical conference in New Orleans focused on African-American physicians and the need for a diverse pool of participants in clinical studies.  Join us on this insightful journey as we help you navigate the sea of medical misinformation and bring you closer to the real truth behind medical research.Be a part of advancing science by participating in clinical researchShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramTwitterLinkedIn Powered by ENCORE Research GroupMusic: Storyblocks - Corporate InspiredThank you for listening!

What We Learned at the ADA Scientific Sessions TAKING CONTROL OF YOUR DIABETES® - THE PODCAST! ...With Expert Endocrinologists Living with T1D, Drs. Steven V. Edelman & Jeremy PettusWe're talking highlights from the ADA Scientific Sessions! As one of the biggest medical diabetes conferences of the year, this event brings together thousands of experts, clinicians, and researchers to talk about the most exciting data and developments happening in diabetes right now.  And we're breaking down what you need to know. Tune in to hear about the latest cutting-edge research in diabetes treatments and how they could affect your management.Questions We'll Cover in This Episode: What is new with GLP-1 drugs? Can you prevent type 1 diabetes?  What is going on with once-weekly basal insulin?  How should you set a target for LDL cholesterol? How have the targets changed over the years? How do doctors measure and monitor kidney disease? What is happening with non-insulin therapies for type 1 diabetes?  ONE 2023 - https://events.blackthorn.io/en/36jDRT6/g/TCOYDCal/one-2023-in-person-august-18-20th-4a3cEY1N4n/overviewDiatribe - https://diatribe.org/JEREMY PETTUS, MDAssociate Professor, University of California, San Diego Health Systems; Director, Type 1 Track & CME, TCOYD; Co-Creator of We Are One DiabetesEUGENE WRIGHT, MDMedical Director, Performance Improvement; Charlotte Area Health Education Center (AHEC)JOHN B. BUSE, MD, PhDVerne S. Caviness Distinguished Professor; Director, Diabetes Center; Director, NC Translational and Clinical Sciences Institute; Senior Associate Dean, Clinical Research; University of North Carolina School of MedicineATHENA PHILIS-TSIMIKAS, MDCorporate VP, Scripps Whittier Diabetes Institute; Director of Community Engagement, Clinical Translational Science Award, Scripps Research Translational Institute; Co-Leader, Scripps Ambulatory Health Equity Council; Associate Clinical Professor of Medicine (voluntary), UCSDJUAN PABLO FRIAS, MDMedical Director and Principal Investigator, Velocity Clinical Research, Los Angeles; Assistant Clinical Professor of Medicine, UCSD**Tune in for 2 new episodes each month! Like what you hear and want to help us grow? Please rate and review this podcast so we can reach more people living with diabetes!** ★ Support this podcast ★

In this specialist spotilight, Drs. Yiu and Emami-Naeini share their insights into Diversity, Equity and Inclusion in retinal medicine including research looking at racial diversity in ophthalmology residency programs, gender disparities in ophthalmology, the need for diversity in clinical trials, and more.

The Osteosarcoma Institute (OSI) is currently supporting two clinical trials and seven laboratory research projects for osteosarcoma. In this OsteoBites episode, you will meet Lee J. Helman, MD, Director of the OSI and Chand Khanna, DVM, PhD, Chair of the OSI's Strategic Advisory Board. Dr. Helman and Dr. Khanna will provide an overview of the OSI's osteosarcoma research portfolio and explain how the OSI identifies promising osteosarcoma research projects. Lee J. Helman, MD has been studying the biology and caring for pediatric patients with sarcomas for over thirty years. Dr. Helman completed his post-doctoral training at the National Cancer Institute (NCI). He then became Head of the Molecular Oncology Section, Pediatric Oncology Branch, NCI, in 1993. He served as Chief of the Pediatric Oncology Branch from 1997-2007 and served as Scientific Director for Clinical Research in the Center for Cancer Research, National Cancer Institute from 2007 to 2016. He joined Children's Hospital Los Angeles (CHLA) and the University of Southern California (USC) in 2017 as the Section Head of Basic and Translational Research within the Cancer and Blood Disease Institute (CBDI) and the Division of Hematology, Oncology and Blood and Marrow Transplantation. He remains an adjunct professor at CHLA. He has also trained many investigators in the field of pediatric sarcomas over the course of his career. He is currently focusing on improving outcomes in osteosarcoma as the Director of the Osteosarcoma Institute. Chand Khanna, DVM, PhD is Chief Science Officer with Ethos Veterinary Health, and President of Ethos Discovery(501c3), its incubator of scientific innovation. His responsibility at Ethos Discovery is to develop innovations in the form of novel diagnostics and therapeutics for both human and animal patients afflicted with similar complex disease conditions (i.e., osteosarcoma; so called Comparative Oncology). Dr. Khanna is a veterinary oncologist and both osteosarcoma and metastasis biologist, who has worked in this scientific field for over 20 years, most notably as a senior investigator of the Tumor and Metastasis Biology section of the Pediatric Oncology Branch at the National Cancer Institute and founding Director of its Comparative Oncology Program. Dr. Khanna's research career has focused on improving the understanding of the biology of metastasis in osteosarcoma and the use of a cross species (mouse, dog, human), Comparative and translational approach to develop novel therapeutics for osteosarcoma metastasis. He serves as the Chair of the Osteosarcoma Institute's Strategic Advisory Board. --- What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

Jennifer Jones-McMeans, Divisional Vice President of Global Clinical Affairs at Abbott, discusses Abbot's new diversity initiative to help address mistrust and societal barriers that underrepresented populations face in receiving healthcare and participating in clinical trials. Through partnerships, clinical research coordinators from diverse backgrounds working in smaller institutions are trained to work with these populations. Norton Health with the Institute for Health Equity is putting funding and infrastructure in place to build a research program model for historically Black colleges and universities to attract more diverse participation in trials and build more vital research institutions.      Jennifer explains, "I had a good conversation with a physician today from the New York area, and we talked about one barrier that is translation. We discussed that the clinical trial this individual is working on did not have the resources for translation services. And so, if you think about something as simple as that, it means that patients who are non-English speaking, their family members, and researchers cannot even approach them because they may not have the translated material. That's one very simple barrier. We can go back to also time - patient time is critical. If you think about individuals who are working and who have family obligations, how do we actually reduce the barrier of time?" "Well, this is where when we think about race and ethnicity, race is not biologic. Remember, it's a social construct. Ethnicity is a social construct. Yes, if you look geographically, we're 99.9% similar when it comes to human genomes. Who I am as an African-American female, I may have far more genetic similarities to someone who is not of African descent. We first have to dispel that. Yes, there can be genetic elements. We do know that geographically you may see a higher frequency of certain genetic associations and whatnot. But I think it becomes less about this because genetics and race are not biologic."   "When you think about who do I need to include? You have to bring in this whole concept of social determinants of health, or also concepts where people, cultures, groups, individuals are impressed not only by the biology but what their surroundings are."   #Abbott #ClinicalTrials #DiversityinClinicalTrials #DiversityResearch #Healthcare #SDOH #SocialDeterminantsofHealth  Abbott.com Download the transcript here

Jennifer Jones-McMeans, Divisional Vice President of Global Clinical Affairs at Abbott, discusses Abbott's new diversity initiative to help address mistrust and societal barriers that underrepresented populations face in receiving healthcare and participating in clinical trials. Through partnerships, clinical research coordinators from diverse backgrounds working in smaller institutions are trained to work with these populations. Norton Health with the Institute for Health Equity is putting funding and infrastructure in place to build a research program model for historically Black colleges and universities to attract more diverse participation in trials and build more vital research institutions.      Jennifer explains, "I had a good conversation with a physician today from the New York area, and we talked about one barrier that is translation. We discussed that the clinical trial this individual is working on did not have the resources for translation services. And so, if you think about something as simple as that, it means that patients who are non-English speaking, their family members, and researchers cannot even approach them because they may not have the translated material. That's one very simple barrier. We can go back to also time - patient time is critical. If you think about individuals who are working and who have family obligations, how do we actually reduce the barrier of time?" "Well, this is where when we think about race and ethnicity, race is not biologic. Remember, it's a social construct. Ethnicity is a social construct. Yes, if you look geographically, we're 99.9% similar when it comes to human genomes. Who I am as an African-American female, I may have far more genetic similarities to someone who is not of African descent. We first have to dispel that. Yes, there can be genetic elements. We do know that geographically you may see a higher frequency of certain genetic associations and whatnot. But I think it becomes less about this because genetics and race are not biologic."   "When you think about who do I need to include? You have to bring in this whole concept of social determinants of health, or also concepts where people, cultures, groups, individuals are impressed not only by the biology but what their surroundings are."   #Abbott #ClinicalTrials #DiversityinClinicalTrials #DiversityResearch #Healthcare #SDOH #SocialDeterminantsofHealth  Abbott.com Listen to the podcast here

Interview Preparation Client Lands CRA Job Don't forget to Subscribe for new content! Merch: https://teespring.com/stores/elite-cl... Subscribe:    / eliteclinicalrese...   Email: eliteclinicalgroup@gmail.com Podcast: https://anchor.fm/clinical-research-p... Steemit: https://steemit.com/@ecrgmedia Advertise: eliteclinicalgroup@gmail.com Watch: » Industry News: https://goo.gl/fNXpQ5 » All Videos: https://goo.gl/87XEFW » Interview Recaps: https://goo.gl/wJsk6W » Glassdoor Reviews: https://goo.gl/AbQzqe We do: » Insider Interviews » Resume Reviews » Question and Answer » Discuss all things Clinical Research » News and Product Reviews » Education ------------------------------------------------------------------------------------------------------------ Elite Clinical Research Group or ECRG for short is a content creating conglomerate that offers many services to individuals in the clinical research and pharmaceutical space. We always keep our "Why" of improving patients lives in mind with everything we do and are always looking to partner with people that are of like mind. Clinical Research is one of the hottest fields in the world right now and thousands of college graduates, masters candidates and phd graduates are looking to enter the clinical research world. Reach out by comment or email if we can help in any way. --- Send in a voice message: https://podcasters.spotify.com/pod/show/clinical-research-podcast/message

Did you ever expect theoretical physics and clinical research could share a common thread? Our latest MedEvidence Monday Minute Radio Show is an intriguing exploration of the ties between theoretical physics and clinical research. Dr. Koren and Kevin Geddings discuss the practical side of clinical research and the crucial need to comprehend risks and probabilities with an anecdote from the Oppenheimer movie. Dr. Koren illuminates the powerful parallels between the predictive nature of theoretical physics and the principles applied in clinical trials. From the conception of the atom bomb to the development of cutting-edge medical treatments, he brilliantly demonstrates how understanding mathematical models can shape the future. Be a part of advancing science by participating in clinical researchShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramTwitterLinkedIn Powered by ENCORE Research GroupMusic: Storyblocks - Corporate InspiredThank you for listening!

Link to the book: https://www.amazon.com/Live-Like-Career-Cowboy-Successfully/dp/B097X4R9W5/ref=sr_1_1?crid=2I4IIQ5Z8KI7U&keywords=live+like+a+career+cowboy&qid=1689956007&sprefix=live+like+a+career+cowboy%2Caps%2C158&sr=8-1Veeva Site Vault: https://sites.veeva.com/Versatrial: http://www.versatrial.ioCRIO: http://www.clinicalresearch.ioInato: https://go.inato.com/3VnSro6Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256My podcast is Random Musings From The Clinical Trials GuruListen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/dp/1090349521/...Text "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/My TikTok: DanSferaLifeBoost Coffee: https://lifeboostcoffee.com/products/biotics-brew?_pos=2&_sid=576df78bc&_ss=r&nb_platform=shareasale

Clinical research manager within the department of oncology here at the Dell Medical School, Monae Carpenter, guides us through her career in research while also giving her perspective on how clinical research trials can better be understood and demystified.

Learn about the cost- and time-saving benefits of basing early phase and first in human clinical trials in Canada.

Resume Review Client Gets Job As a Remote CRA Don't forget to Subscribe for new content! Merch: https://teespring.com/stores/elite-cl... Subscribe:    / eliteclinicalrese...   Email: eliteclinicalgroup@gmail.com Podcast: https://anchor.fm/clinical-research-p... Steemit: https://steemit.com/@ecrgmedia Advertise: eliteclinicalgroup@gmail.com Watch: » Industry News: https://goo.gl/fNXpQ5 » All Videos: https://goo.gl/87XEFW » Interview Recaps: https://goo.gl/wJsk6W » Glassdoor Reviews: https://goo.gl/AbQzqe We do: » Insider Interviews » Resume Reviews » Question and Answer » Discuss all things Clinical Research » News and Product Reviews » Education ------------------------------------------------------------------------------------------------------------ Elite Clinical Research Group or ECRG for short is a content creating conglomerate that offers many services to individuals in the clinical research and pharmaceutical space. We always keep our "Why" of improving patients lives in mind with everything we do and are always looking to partner with people that are of like mind. Clinical Research is one of the hottest fields in the world right now and thousands of college graduates, masters candidates and phd graduates are looking to enter the clinical research world. Reach out by comment or email if we can help in any way. --- Send in a voice message: https://podcasters.spotify.com/pod/show/clinical-research-podcast/message

Featuring perspectives from Dr Emmanuel S Antonarakis, Prof Karim Fizazi, Dr Rana R McKay, Dr Alicia K Morgans and Dr A Oliver Sartor, including the following topics: Current Management of Nonmetastatic Prostate Cancer Introduction (0:00) Case: A man in his early 70s diagnosed with localized prostate cancer who underwent a radical prostatectomy in 2010 experiences rising prostate-specific antigen (PSA) from 0.18 to 0.4; PSA doubling time 7 months; PSMA PET-negative for other sites of disease — David S Morris, MD (1:26) Case: A man in his early 70s with M0 hormone-sensitive prostate cancer (HSPC) with PSA persistence after radical prostatectomy received androgen deprivation therapy (ADT) intensification with abiraterone/prednisone and went to the ER with hypertension, palpitations, headache and abnormal liver function tests — Sandy Srinivas, MD (15:58) Faculty presentation: Dr Morgans (19:29) New Considerations in Treatment Intensification for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Case: A man in his mid 60s with localized prostate cancer and biochemical recurrence 5 years after neoadjuvant and adjuvant leuprolide and intensity-modulated radiotherapy to the whole pelvis — Neeraj Agarwal, MD, FASCO (28:59) Case: A man in his early 80s who underwent radical prostatectomy 15 years ago and received radiotherapy and ADT for biochemical recurrences is now diagnosed with M0 castration-resistant prostate cancer with quickly rising PSA levels — Dr Morris (33:02) Faculty presentation: Prof Fizazi (41:54) Available and Emerging Strategies for Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer (mCRPC) Discussion (53:41) Case: A man in his mid 60s diagnosed with metastatic HSPC and PSMA positivity in the pubic ramus, bilateral external iliac nodes and lungs — Dr Srinivas (57:03) Faculty presentation: Dr McKay (1:03:01) Identification and Management of mCRPC with a Homologous Recombination Repair (HRR) Gene Abnormality Case: A man in his early 50s with mCRPC after enzalutamide receives olaparib; somatic BRCA2 mutation; TP53 mutation on liquid biopsy — Dr Agarwal (1:18:21) Case: A man in his early 70s with high-grade localized prostate cancer treated with proton beam therapy and ADT for 2 years now has rising PSA and CT scan positive for retroperitoneal node; somatic BRCA2, TP53, FOXA1 and MEN1 mutations; microsatellite stable — Dr Morris (1:21:59) Faculty presentation: Dr Antonarakis (1:30:22) Management of Progressive mCRPC Case: A man in his late 70s with multiregimen-refractory mCRPC and a gBRCA2 mutation receives olaparib with a sustained response for several years — Dr Srinivas (1:43:10) Faculty presentation: Dr Sartor (1:48:35) CME information and select publications

DENTAL ONLINE TRAINING link DOT: Use DENTALDIGEST for 10% off  Follow @dental_digest_podcast Instagram Follow @dr.melissa_seibert on Instagram Connect with Melissa on Linkedin Dr. Kokich Jr. received his dental degree from Tufts University School of Dental Medicine in 1996 and completed a general practice residency at the University of Washington Medical Center in 1997. He remained at the University of Washington for his orthodontic training where he obtained his Masters in Orthodontics in 1999. Since then he has remained on faculty in the Department of Orthodontics as an Affiliate Assistant Professor while maintaining a private practice in Tacoma, Washington. He has received the Charles L. Pincus Research Award for Clinical Research from the American Academy of Esthetic Dentistry and his current research and publications are primarily involved with esthetic, interdisciplinary dentistry. He is a diplomate of the American Board of Orthodontists and a member of both the Angle Society and the American Academy of Esthetic Dentistry. He has written or co-written four book chapters as well as numerous scientific and review articles. Dr. Kokich Jr. has given over 240 lectures nationally and internationally on interdisciplinary dentistry and dental esthetics emphasizing comprehensive treatment planning and the importance of properly sequencing orthodontic, periodontal, and restorative treatment.